Nevertheless, additional research is necessary to ascertain whether RNF112 suppresses lipid biosynthesis in BLCA via ACLY and to assess the viability of ACLY as a potential therapeutic target for BLCA. This evidence concerns the gene RNF112 and bladder transitional cell carcinoma.